Jenell Stewart
Overview
Explore the profile of Jenell Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Violette L, Corcorran M, Austin E, Williams E, Glick S, Dhanireddy S, et al.
AIDS Behav
. 2025 Feb;
PMID: 39899230
Women who inject drugs (WWID) are disproportionately affected by HIV and experience multiple barriers to PrEP use. We conducted a mixed methods study to assess PrEP awareness, interest, and use,...
2.
Irie W, Nicol M, Clement M, Bukusi E, Bekker L, Molina J, et al.
Lancet HIV
. 2025 Jan;
12(2):e143-e153.
PMID: 39788131
Despite advancements in existing antiretroviral-based prevention strategies, including daily oral, locally acting, and injectable options, there is a pressing need for more inclusive and flexible event-driven pre-exposure prophylaxis (PrEP) strategies...
3.
Stewart J, Gandhi M, Bukusi E
N Engl J Med
. 2024 Apr;
390(13):1249.
PMID: 38598594
No abstract available.
4.
Hazra A, McNulty M, Pyra M, Pagkas-Bather J, Gutierrez J, Pickett J, et al.
Clin Infect Dis
. 2024 Feb;
PMID: 38332660
Over the past two decades, cases of sexually transmitted infections (STIs) due to syphilis, gonorrhea, and chlamydia have been rising in the United States, disproportionately among gay, bisexual, and other...
5.
Stewart J, Oware K, Donnell D, Violette L, Odoyo J, Soge O, et al.
N Engl J Med
. 2023 Dec;
389(25):2331-2340.
PMID: 38118022
Background: Doxycycline postexposure prophylaxis (PEP) has been shown to prevent sexually transmitted infections (STIs) among cisgender men and transgender women, but data from trials involving cisgender women are lacking. Methods:...
6.
Mogaka F, Stewart J, Omollo V, Bukusi E
Curr HIV/AIDS Rep
. 2023 Sep;
20(5):312-319.
PMID: 37751130
Purpose Of Review: This article reviews current efforts to control bacterial sexually transmitted infections (STIs) among HIV pre-exposure prophylaxis (PrEP) users and outlines the opportunities and challenges to controlling STIs...
7.
Oware K, Adiema L, Rono B, Violette L, McClelland R, Donnell D, et al.
BMC Womens Health
. 2023 Jun;
23(1):296.
PMID: 37270546
Introduction: The global incidence of sexually transmitted infections (STIs) has been rapidly increasing over the past decade, with more than one million curable STIs being acquired daily. Young women in...
8.
Steinbronn C, Chhonker Y, Stewart J, Leingang H, Heller K, Krows M, et al.
Clin Transl Sci
. 2023 Apr;
16(7):1243-1257.
PMID: 37118968
Hydroxychloroquine (HCQ) is Food and Drug Administration (FDA)-approved for malaria, systemic and chronic discoid lupus erythematosus, and rheumatoid arthritis. Because HCQ has a proposed multimodal mechanism of action and a...
9.
Soge O, Issema R, Bukusi E, Baeten J, Mujugira A, Celum C, et al.
Sex Transm Dis
. 2023 Feb;
50(5):317-319.
PMID: 36728331
Using archived Neisseria gonorrhoeae samples from 2008 to 2012, the prevalence of tet (M) genemediating high-level tetracycline resistance in N. gonorrhoeae was 96% among 50 Kenyan women. Determining the local...
10.
Kumbhakar R, Neradilek M, Barnabas R, Stewart J, Stankiewicz Karita H, Landovitz R, et al.
J Med Virol
. 2022 Aug;
94(12):6091-6096.
PMID: 35940869
Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted...